MacroGenics reported $130.69M in Cash and Equivalent for its fiscal quarter ending in June of 2025.


Cash And Equivalent Change Date
AbbVie USD 5.18B 349M Mar/2025
Amgen USD 8.03B 782M Jun/2025
AstraZeneca USD 7.06B 1.83B Jun/2025
Biogen USD 2.76B 160.5M Jun/2025
Bristol-Myers Squibb USD 12.6B 1.72B Jun/2025
Daiichi Sankyo JPY 639.84B 42.31B Mar/2025
Eli Lilly USD 3.38B 282.6M Jun/2025
Genmab DKK 1.3B 323M Jun/2025
Geron USD 79.6M 6.01M Jun/2025
Gilead Sciences USD 5.14B 2.78B Jun/2025
J&J USD 38.47B 32.35B Mar/2025
MacroGenics USD 130.69M 52.15M Jun/2025
Merck USD 8.01B 622M Jun/2025
Pfizer USD 1.64B 208M Jun/2025
Regeneron Pharmaceuticals USD 2B 1.09B Jun/2025
Roche Holding CHF 6.98B 2.15B Dec/2024
Xencor USD 44.44M 4.77M Jun/2025